Actinium Pharmaceuticals. has filed a patent for humanized anti-human CD45 antibodies and pharmaceutical compositions containing these antibodies. The claim specifies the sequences of the heavy and light chain variable regions required for the antibody or antibody fragment. GlobalData’s report on Actinium Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Actinium Pharmaceuticals, Antibody drug conjugates(ADC) cancer therapy was a key innovation area identified from patents. Actinium Pharmaceuticals's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized anti-human cd45 antibody pharmaceutical compositions
The patent application (Publication Number: US20240010744A1) discloses a series of claims related to anti-huCD45 antibodies or huCD45-binding antibody fragments. The first claim specifies the sequences of the immunoglobulin heavy chain variable region and light chain variable region, with a particular restriction on the combination when certain sequences are involved. The second claim further defines the sequences of the immunoglobulin heavy chain and light chain. Moving on, the third claim details the specific sets of immunoglobulin heavy chain complementarity determining regions (CDRs) and light chain CDRs. These claims aim to protect the unique antibody structures designed for targeting huCD45.
Moreover, the patent application includes claims related to pharmaceutical compositions containing the antibodies or fragments, as well as radiopharmaceutical compositions where the antibodies are linked to radionuclides. The compositions may include various pharmaceutically acceptable excipients and specific radionuclides such as 131I, 225Ac, 177Lu, or 90Y. Additionally, there are claims for compositions where the antibodies are chemically conjugated to chelators like DOTA, along with the option of including radionuclides chelated by the chelator. These claims highlight the potential applications of the antibodies in pharmaceutical and radiopharmaceutical compositions, emphasizing their therapeutic and diagnostic uses in targeting huCD45.
To know more about GlobalData’s detailed insights on Actinium Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
